Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neurodevelopmental Disorders Caused by De Novo Variants in KCNB1 Genotypes and Phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Association of Childhood Body Mass Index and Change in Body Mass Index With First Adult Ischemic Stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Current understanding of thalamic structure and function in migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Calcitonin gene-related peptide - beyond migraine prophylaxis

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [11C]DASB PET study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Development and Evaluation of Two Potential 5-HT7 Receptor PET Tracers: [18F]ENL09 and [18F]ENL10

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Importance: Triptans, the most efficient acute treatment for migraine attacks, are 5-HT1B/1D receptor agonists, but their precise mechanism of action is not completely understood. The extent to which triptans enter the central nervous system and bind to 5-HT1B receptors in the brain is unknown.

Objectives: To determine the occupancy of sumatriptan to central 5-HT1B receptors, and to investigate changes in brain serotonin levels during migraine attacks.

Design, Setting, and Participants: This study of 8 patients in Denmark used a within-participant design and was conducted from April 20, 2015, to December 5, 2016. Participants were otherwise healthy patients with untreated episodic migraine without aura, aged between 18 and 65 years, and recruited from the general community. Data analysis was performed from January 2017 to April 2018.

Interventions: All participants underwent positron emission tomographic scans after injection of [11C]AZ10419369, a specific 5-HT1B receptor radiotracer. All participants were scanned 3 times: (1) during an experimentally induced migraine attack, (2) after a subcutaneous injection of 6-mg subcutaneous sumatriptan, and (3) on a migraine attack-free day. Scans 1 and 2 were conducted on the same study day. Each scan lasted for 90 minutes.

Main Outcome and Measure: The primary outcome was the nondisplaceable binding potential of [11C]AZ10419369 across 7 brain regions involved in pain modulation. The binding potential reflects receptor density, and changes in binding potential reflects displacement of the radiotracer. The occupancy of sumatriptan was estimated from the 2 scans before and after sumatriptan administration.

Results: Eight patients with migraine were included in the study; of these participants, 7 (87%) were women. The mean (SD) age of participants on study day 1 was 29.5 (9.2) years and on study day 2 was 30.0 (8.9) years. Sumatriptan was associated with statistically significantly reduced 5-HT1B receptor binding across pain-modulating regions (mean [SD] binding potential, 1.20 [0.20] vs 1.02 [0.22]; P = .001), corresponding to a mean (SD) drug occupancy rate of 16.0% (5.3%). Furthermore, during migraine attacks, as compared with outside of attacks, 5-HT1B receptor binding was statistically significantly associated with reduced in pain-modulating regions (mean [SD] binding potential, 1.36 [0.22] vs 1.20 [0.20]; P = .02).

Conclusions and Relevance: Treatment with sumatriptan during migraine attacks appeared to be associated with a decrease in 5-HT1B receptor binding, a finding that is most likely associated with the binding of sumatriptan to central 5-HT1B receptors, but the contribution of ongoing cerebral serotonin release to the lower binding cannot be excluded; the migraine attack-associated decrease in binding could indicate that migraine attacks are associated with increases in endogenous serotonin.

Original languageEnglish
JournalJAMA Neurology
Volume76
Issue number7
Pages (from-to)834-840
Number of pages7
ISSN2168-6149
DOIs
Publication statusPublished - 1 Jul 2019

ID: 58077244